Final Dose
Final Dose is developing a programmable cancer therapy architecture that uses DNA-level genetic addresses to identify malignant cells and a scalable platform to deploy treatments across multiple tumor types. The company's framework integrates genetic targeting with programmable therapeutic delivery, aiming to move beyond single-disease solutions toward a systematic approach to cancer elimination.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Raised to date
$500KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Current cancer therapies often lack the precision to target malignant cells at the genetic level while also struggling to scale across diverse patient populations and tumor types. This limits treatment effectiveness and hinders progress toward comprehensive disease elimination.
Solution
Final Dose is building a complete architecture for cancer therapy that integrates DNA-level targeting with programmable treatment platforms. The company's approach uses genetic addresses to precisely identify cancer cells, while programmability enables scalable therapeutic deployment across different cancer types. By combining these elements, Final Dose aims to create a unified framework that moves beyond one-off treatments toward a systematic, adaptable cancer care model. Their architecture is designed to support the eventual goal of disease elimination through repeatable, programmable interventions.
Target Audience
Primary stakeholders are oncology researchers, clinical development teams, and healthcare providers seeking programmable, DNA-targeted approaches to cancer treatment and elimination.
Features
- DNA-level targeting system that identifies cancer cells through genetic address mapping
- Programmable therapeutic platform designed for scalable treatment deployment
- Unified architecture connecting genetic identification with treatment delivery
- Framework designed to support multiple cancer types through adaptable programming
- Technology approach intended to move beyond single-disease solutions toward comprehensive care